TFAP2E-DKK4 and chemoresistance in colorectal cancer

Ebert, Matthias P A; Tänzer, Marc; Balluff, Benjamin; Burgermeister, Elke; Kretzschmar, Antje Karen; Hughes, David J; Tetzner, Reimo; Lofton-Day, Catherine; Rosenberg, Robert; Reinacher-Schick, Anke C; Schulmann, Karsten; Tannapfel, Andrea; Hofheinz, Ralf; Röcken, Christoph; Keller, Gisela; Langer, Rupert; Specht, Katja; Porschen, Rainer; Stöhlmacher-Williams, Jan; Schuster, Tibor; ... (2012). TFAP2E-DKK4 and chemoresistance in colorectal cancer. New England journal of medicine NEJM, 366(1), pp. 44-53. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa1009473

[img]
Preview
Text
nejmoa1009473.pdf - Published Version
Available under License Publisher holds Copyright.

Download (869kB) | Preview

Chemotherapy for advanced colorectal cancer leads to improved survival; however, predictors of response to systemic treatment are not available. Genomic and epigenetic alterations of the gene encoding transcription factor AP-2 epsilon (TFAP2E) are common in human cancers. The gene encoding dickkopf homolog 4 protein (DKK4) is a potential downstream target of TFAP2E and has been implicated in chemotherapy resistance. We aimed to further evaluate the role of TFAP2E and DKK4 as predictors of the response of colorectal cancer to chemotherapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Langer, Rupert

ISSN:

0028-4793

Publisher:

Massachusetts Medical Society MMS

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:32

Last Modified:

23 Oct 2019 16:35

Publisher DOI:

10.1056/NEJMoa1009473

PubMed ID:

22216841

Web of Science ID:

000299968800006

BORIS DOI:

10.7892/boris.12527

URI:

https://boris.unibe.ch/id/eprint/12527 (FactScience: 218881)

Actions (login required)

Edit item Edit item
Provide Feedback